Geographic Variation in the Treatment of Acute Myocardial Infarction

Abstract
Each year approximately 1.5 million people in the United States experience acute myocardial infarction (AMI), and approximately one third of these patients die in the acute phase of the AMI. The annual economic burden of AMI is in excess of $60 billion.1 Due to its frequency and severity, AMI has been the topic of intense scientific and clinical interest. Randomized trials have confirmed the efficacy of some therapies resulting in evidence-based treatment guidelines.2,3 These guidelines make it possible to evaluate the processes of care in a meaningful manner and to identify areas for the improvement of the care of patients with AMI.

This publication has 1 reference indexed in Scilit: